Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Travere Therapeutics(US:TVTX) Seeking Alphaยท2024-09-30 12:00Company Overview - Travere Therapeutics, Inc. (NASDAQ: TVTX) focuses on treatments for rare kidney and metabolic diseases [1] - The company's portfolio includes FDA-approved drugs such as Filspari (Sparsentan) for IgA Nephropathy (IgAN) and Thiola (Tiopronin) for cystinuria [1] Recent Developments - Filspari received full FDA approval in September 2024, which expanded its label and increased patient access [1]